Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Rating Reaffirmed by Benchmark

Benchmark restated their speculative buy rating on shares of Anebulo Pharmaceuticals (NASDAQ:ANEB) in a research report sent to investors on Tuesday morning, MarketBeat.com reports. The firm currently has a $8.00 target price on the stock.

Anebulo Pharmaceuticals Stock Performance

Anebulo Pharmaceuticals stock opened at $1.90 on Tuesday. Anebulo Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $3.61. The firm’s 50-day simple moving average is $2.01 and its 200 day simple moving average is $2.33. The stock has a market cap of $49.27 million, a PE ratio of -5.27 and a beta of -1.01.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last announced its earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. As a group, analysts predict that Anebulo Pharmaceuticals will post -0.48 EPS for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.